This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein Dental Software Arm May Rebound Despite Pandemic
by Zacks Equity Research
Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
Illumina Takes Over BlueBee, Fortifies NGS Data Processing
by Zacks Equity Research
With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block
by Zacks Equity Research
With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.
Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management
by Zacks Equity Research
Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.
HOLX or ABMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. ABMD: Which Stock Is the Better Value Option?
Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS
by Zacks Equity Research
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA
by Zacks Equity Research
Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.
Why Is Hologic (HOLX) Up 4.4% Since Last Earnings Report?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HOLX vs. ABMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. ABMD: Which Stock Is the Better Value Option?
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
by Sreoshi Bera
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
by Zacks Equity Research
Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Hologic (HOLX) Q2 Earnings Top Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 5.56% and 0.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Apr 29: BSX, ALGN & More
by Urmimala Biswas
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products.
Earnings Preview: Hologic (HOLX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.
Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.